Toxicology – Deferoxamine

Core Concept

Deferoxamine (DFO) is a parenteral chelating agent used primarily for clinically significant iron poisoning and for selected chronic iron- or aluminum-overload states.

In acute toxicology, its major role is:

Severe acute iron poisoning → deferoxamine chelation

It binds toxic circulating and tissue-accessible ferric iron (Fe³⁺), forming a less toxic, water-soluble complex called ferrioxamine.

Why Iron Becomes Toxic

Iron is normally safely incorporated into proteins such as:

• Hemoglobin
• Ferritin
• Transferrin
• Hemosiderin
• Iron-containing enzymes

After a sufficiently large acute exposure, normal binding capacity can become overwhelmed.

Excess free iron can then cause:

• Direct gastrointestinal corrosive injury
• Oxidative stress and free-radical formation
• Mitochondrial dysfunction
• Cellular injury
• Vasodilation and shock
• Metabolic acidosis
• Hepatic injury

Mechanism of Deferoxamine

Deferoxamine has a high affinity for ferric iron.

The basic reaction is:

Deferoxamine + Fe³⁺ → ferrioxamine

Ferrioxamine is considerably less biologically reactive than free iron and can subsequently be eliminated.

What Deferoxamine Does NOT Remove

Deferoxamine preferentially binds accessible toxic iron rather than stripping iron from essential physiologic proteins.

It does not substantially remove iron normally incorporated into:

• Hemoglobin
• Cytochromes
• Ferritin under usual acute treatment conditions
• Transferrin-bound iron under normal saturation conditions

This relative selectivity allows chelation of toxic iron while limiting disruption of essential iron-dependent functions.

Ferrioxamine Elimination

The iron–deferoxamine complex is eliminated substantially through the kidneys.

It can produce the classic:

Pink, reddish, or “vin rosé” urine

However:

Absence of pink or red urine does NOT mean deferoxamine is ineffective and does not exclude serious iron poisoning.

Urine color should never determine whether treatment is necessary.

Clinical Course of Acute Iron Poisoning

Acute iron poisoning classically progresses through several possible phases, although patients do not always follow a textbook sequence.

Early GI Phase

Possible findings include:

• Vomiting
• Abdominal pain
• Diarrhea
• Hematemesis
• Hematochezia
• Lethargy

Severe GI symptoms suggest significant corrosive and systemic toxicity.

Apparent Improvement

Symptoms may temporarily improve.

This latent period can be misleading because systemic toxicity may still evolve.

Systemic Toxicity

Severe poisoning may produce:

• Tachycardia
• Hypotension
• Shock
• High-anion-gap metabolic acidosis
• Altered mental status
• Seizures
• Coagulopathy
• Multiorgan dysfunction

Hepatic Injury

Delayed severe poisoning may produce:

• Markedly elevated aminotransferases
• Hypoglycemia
• Coagulopathy
• Acute liver failure

Late GI Scarring

Weeks later, severe corrosive GI injury can occasionally cause:

• Gastric outlet obstruction
• Other gastrointestinal strictures

When to Consider Deferoxamine

Chelation is primarily considered when there is evidence of significant systemic iron toxicity.

Important clinical findings include:

• Persistent severe vomiting or diarrhea
• GI bleeding
• Altered mental status
• Persistent tachycardia
• Hypotension or shock
• Significant metabolic acidosis
• Evidence of systemic deterioration

The overall clinical condition is more important than any isolated number.

Serum Iron Concentration

A serum iron concentration can help estimate severity when obtained at an appropriate time after an acute ingestion.

Important principles:

• Obtain the concentration during the expected absorption period.
• Interpret it together with symptoms and timing.
• A concentration obtained too early may underestimate the eventual peak.
• Delayed-release preparations can complicate interpretation.
• A single value should not override severe clinical toxicity.

Historically, concentrations around or above 500 µg/dL have been associated with substantial toxicity, but modern treatment decisions should not depend on a rigid threshold alone.

Do Not Delay Treatment in Severe Poisoning

A critically ill patient with a convincing iron exposure and manifestations such as:

• Shock
• Severe acidosis
• Significant CNS toxicity

may require chelation before a definitive serum iron result becomes available.

Clinical deterioration takes priority over waiting for laboratory confirmation.

Serum Iron After Deferoxamine

Once deferoxamine has been administered, interpretation of some serum iron measurements becomes problematic because laboratory methods may measure iron differently in the presence of chelator or ferrioxamine.

Therefore:

Pre-chelation iron concentrations are generally more useful for initial assessment.

Subsequent treatment should emphasize the overall clinical course rather than repeatedly chasing potentially misleading iron values.

TIBC Is Not a Reliable Severity Test

Historically, clinicians sometimes compared serum iron with total iron-binding capacity (TIBC).

This is unreliable in acute poisoning.

TIBC should not be used to determine:

• Whether serious toxicity exists
• Whether chelation is required
• When deferoxamine should be stopped

Route of Administration

For significant acute systemic iron poisoning:

Continuous IV deferoxamine is preferred.

Intramuscular administration is generally unsuitable for seriously poisoned patients because:

• Absorption may be unreliable
• Shock reduces muscle perfusion
• IV access is already necessary for resuscitation
• IM administration can cause local pain and complications

Oral deferoxamine is not appropriate for systemic chelation.

Duration of Therapy

Deferoxamine should be individualized according to:

• Hemodynamic improvement
• Resolution of metabolic acidosis
• Improvement in mental status
• Reduction of GI/systemic toxicity
• Renal function
• Overall clinical course

Many acute cases do not require prolonged treatment.

Long treatment courses increase the risk of adverse effects.

Hypotension

One of the most important acute adverse effects of deferoxamine is hypotension, particularly when administered too rapidly.

This is especially problematic because severe iron poisoning itself can cause:

• Vasodilation
• Volume depletion
• Shock

If hypotension develops during therapy, consider both the poisoning and treatment as possible contributors.

Hypersensitivity Reactions

Deferoxamine can rarely cause:

• Flushing
• Urticaria
• Hypotension
• Anaphylactoid or hypersensitivity reactions

Rapid administration can increase the risk of hemodynamic adverse effects.

Pulmonary Toxicity

Prolonged high-intensity deferoxamine treatment in acute poisoning has been associated with:

• Acute lung injury
• Pulmonary edema
• ARDS-like respiratory failure

This is one reason unnecessary prolonged treatment should be avoided.

Yersinia Infection

A distinctive complication of deferoxamine therapy is increased susceptibility to certain infections, particularly:

Yersinia enterocolitica

Deferoxamine can function as a siderophore-like iron source for Yersinia, allowing the organism to access iron more effectively.

This concern is particularly relevant during prolonged therapy or chronic iron overload.

Mucormycosis

Deferoxamine has also been associated with invasive fungal infection caused by Mucorales, particularly in susceptible patients such as those with:

• Renal failure
• Chronic iron or aluminum overload
• Prolonged deferoxamine exposure

This is far less relevant to a brief uncomplicated emergency course but remains an important pharmacologic association.

Ocular Toxicity

Long-term or excessive deferoxamine exposure can cause:

• Reduced visual acuity
• Abnormal color vision
• Visual-field abnormalities
• Night-vision impairment
• Retinal or optic-nerve toxicity

These effects are mainly associated with chronic therapy rather than brief acute chelation.

Auditory Toxicity

Chronic deferoxamine treatment can also produce:

• Tinnitus
• Sensorineural hearing loss

Long-term patients may therefore require periodic auditory assessment.

Renal Function

Renal impairment complicates deferoxamine therapy because ferrioxamine is substantially renally eliminated.

Monitor:

• Creatinine
• Urine output
• Fluid status
• Electrolytes

Renal injury can arise from the original iron poisoning, shock, or treatment-related factors.

Deferoxamine and Dialysis

A key distinction:

Free iron itself is not effectively removed by conventional hemodialysis because of its distribution and protein binding.

However, extracorporeal therapy may have a role in selected patients with:

• Severe renal failure
• Accumulation of ferrioxamine or related complexes
• Severe metabolic or renal complications requiring dialysis independently

This should be managed with toxicology and nephrology input rather than assuming dialysis is routinely indicated for iron poisoning.

Activated Charcoal

Activated charcoal does not effectively adsorb iron.

Therefore:

Iron poisoning → activated charcoal is not useful for the iron itself.

If a mixed ingestion occurred, charcoal might still have a role for an appropriate coingestant, provided the airway and gastrointestinal situation are suitable.

Whole-Bowel Irrigation

Because iron is not effectively bound by charcoal, whole-bowel irrigation (WBI) may be considered in selected substantial ingestions when tablets remain within the gastrointestinal tract.

This is particularly relevant when:

• A large tablet burden is visible on imaging
• The patient has a substantial ingestion
• Gastrointestinal function is adequate

WBI is not appropriate with obstruction, ileus, perforation, severe instability, or an inadequately protected airway.

Abdominal Imaging

Iron tablets are often radiopaque.

Abdominal radiography may therefore demonstrate:

• Tablets
• Pill concretions
• Large retained gastrointestinal burdens

However:

A negative radiograph does not completely exclude iron ingestion.

Imaging is an adjunct to the clinical and laboratory assessment.

Ascorbic Acid

Vitamin C can alter iron mobilization and iron-chelator dynamics.

It is not routinely added to the acute treatment of iron overdose.

Its use in chronic iron-overload therapy is a different situation and requires careful specialist supervision.

Chronic Iron Overload

Repeated blood transfusions can cause progressive iron accumulation because the body has no efficient physiologic mechanism for eliminating large excesses of iron.

Chronic iron overload can damage:

• Liver
• Heart
• Endocrine organs
• Other tissues

Deferoxamine has historically been an important treatment, often through prolonged subcutaneous administration.

Other modern iron chelators, including oral agents, may also be used depending on the underlying condition.

Aluminum Overload

Deferoxamine can also chelate aluminum.

It has historically been used for significant aluminum accumulation, particularly in patients receiving long-term dialysis.

This is now a specialized indication and should be managed with nephrology/toxicology expertise.

Pregnancy

The historical FDA Category C designation is obsolete.

Severe maternal iron poisoning is potentially fatal and itself threatens the fetus.

Therefore:

Pregnancy should not prevent necessary deferoxamine treatment for serious maternal iron poisoning.

Maternal stabilization takes priority.

Monitoring During Acute Iron Poisoning

Important monitoring includes:

• Airway and breathing
• Continuous cardiovascular monitoring in severe cases
• Blood pressure and perfusion
• Mental status
• Blood glucose
• Electrolytes
• Bicarbonate and anion gap
• Blood gas and lactate when severely ill
• Renal function
• Urine output
• Liver enzymes
• Coagulation studies in significant poisoning
• Appropriately timed serum iron concentration

Serial reassessment is essential because toxicity can evolve after an apparent period of improvement.

Important Modernization of the Older Source

Several points require clarification:

• Deferoxamine remains an important antidote for severe systemic iron poisoning.
• Treatment should be based on the overall clinical syndrome, timing, serum iron concentration, metabolic abnormalities, and hemodynamic status—not a rigid serum iron cutoff alone.
• Do not delay deferoxamine in a severely symptomatic patient while awaiting an iron concentration.
• IV infusion is preferred for significant acute poisoning; IM therapy has little role in critically ill patients.
• The classic vin rosé urine finding is neither required nor sufficiently reliable to guide treatment.
• TIBC is not useful for determining the severity of acute iron poisoning.
• Serum iron measurements can become difficult to interpret after chelation begins.
• Activated charcoal does not meaningfully bind iron.
• WBI may be useful for selected large tablet burdens.
• Prolonged deferoxamine treatment increases the risk of pulmonary toxicity and other complications.
• Deferoxamine is associated with Yersinia and, particularly in susceptible chronic-treatment patients, Mucorales infection.
• Hemodialysis does not simply remove the original iron burden; its role is mainly selected renal/metabolic situations and potentially removal of circulating chelated complexes.
• Historical FDA pregnancy categories are obsolete; severe maternal poisoning warrants treatment.

Key Points

• Deferoxamine is a major antidote for severe acute iron poisoning.
• It chelates ferric iron (Fe³⁺) to form ferrioxamine.
• Ferrioxamine is substantially renally eliminated.
• Severe iron toxicity can cause corrosive GI injury, shock, high-anion-gap metabolic acidosis, CNS toxicity, hepatic failure, and multiorgan dysfunction.
• An apparent symptom-free period does not guarantee recovery.
• Severe symptomatic poisoning can justify chelation before the iron concentration returns.
• Serum iron values must be interpreted according to timing and clinical findings.
• TIBC is not a reliable guide to acute iron toxicity.
• IV deferoxamine is preferred for serious systemic poisoning.
• Rapid administration can cause significant hypotension.
• Prolonged treatment can contribute to pulmonary toxicity.
• Chronic therapy can produce ocular and auditory toxicity.
• Deferoxamine is associated with increased susceptibility to Yersinia and certain invasive fungal infections.
• Activated charcoal does not adsorb iron effectively.
• Selected large tablet ingestions may be candidates for whole-bowel irrigation.
• Pink or “vin rosé” urine may occur during chelation, but its absence does not exclude toxicity or treatment effect.
• Pregnancy is not a reason to withhold necessary chelation in life-threatening maternal iron poisoning.